[
  {
    "id": "hc",
    "name": "Health Canada",
    "description": "Regulatory agency that approves drugs for sale and use in Canada.",
    "url": "https://health-products.canada.ca/dpd-bdpp/",
    "last_updated": "2025-06-11"
  },
  {
    "id": "doc:hc.adcetris",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Adcetris (brentuximab vedotin) [product monograph]. HC.",
    "aliases": [],
    "citation": "Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.",
    "company": "Seagen Inc.",
    "drug_name_brand": "Adcetris",
    "drug_name_generic": "brentuximab vedotin",
    "first_published": null,
    "access_date": "2025-06-11",
    "organization_id": "hc",
    "publication_date": "2025-04-08",
    "url": "https://pdf.hres.ca/dpd_pm/00080158.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626",
    "application_number": null
  },
  {
    "id": "doc:hc.afinitor",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Afinitor (everolimus) [product monograph]. HC.",
    "aliases": [],
    "citation": "Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.",
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Afinitor",
    "drug_name_generic": "everolimus",
    "first_published": "2009-12-11",
    "access_date": "2025-06-11",
    "organization_id": "hc",
    "publication_date": "2021-11-30",
    "url": "https://pdf.hres.ca/dpd_pm/00063824.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511",
    "application_number": null
  },
  {
    "id": "doc:hc.akeega",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Akeega (abiraterone acetate and niraparib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Janssen Inc. Akeega (abiraterone acetate and niraparib) [product monograph]. Health Canada Website. https://pdf.hres.ca/dpd_pm/00078864.PDF. Revised March 2025. Accessed June 2025.",
    "company": "Janssen Inc.",
    "drug_name_brand": "Akeega",
    "drug_name_generic": "abiraterone acetate and niraparib",
    "first_published": "2023-06-07",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2025-03-12",
    "url": "https://pdf.hres.ca/dpd_pm/00078864.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102726",
    "application_number": null
  },
  {
    "id": "doc:hc.balversa",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Balversa (erdafitinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.",
    "company": "Janssen Inc.",
    "drug_name_brand": "Balversa",
    "drug_name_generic": "erdafitinib",
    "first_published": "2019-10-25",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-11-20",
    "url": "https://pdf.hres.ca/dpd_pm/00077812.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320",
    "application_number": null
  },
  {
    "id": "doc:hc.besponsa",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Besponsa (inotuzumab ozogamicin) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Besponsa",
    "drug_name_generic": "inotuzumab ozogamicin",
    "first_published": "2018-03-15",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-11-08",
    "url": "https://pdf.hres.ca/dpd_pm/00077730.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383",
    "application_number": null
  },
  {
    "id": "doc:hc.blincyto",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Blincyto (blinatumomab) [product monograph]. HC.",
    "aliases": [],
    "citation": "Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.",
    "company": "Amgen Canada Inc.",
    "drug_name_brand": "Blincyto",
    "drug_name_generic": "blinatumomab",
    "first_published": "2015-12-22",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-12-27",
    "url": "https://pdf.hres.ca/dpd_pm/00078156.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93642",
    "application_number": null
  },
  {
    "id": "doc:hc.bosulif",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Bosulif (bosutinib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Bosulif",
    "drug_name_generic": "bosutinib",
    "first_published": "2014-03-07",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-07-12",
    "url": "https://pdf.hres.ca/dpd_pm/00076285.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368",
    "application_number": null
  },
  {
    "id": "doc:hc.braftovi",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Braftovi (encorafenib) [product monograph]. HC.",
    "aliases": [],
    "citation": "Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.",
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Braftovi",
    "drug_name_generic": "encorafenib",
    "first_published": "2021-03-02",
    "access_date": "2025-06-12",
    "organization_id": "hc",
    "publication_date": "2024-02-23",
    "url": "https://pdf.hres.ca/dpd_pm/00074711.PDF",
    "url_drug": "https://health-products.canada.ca/dpd-bdpp/dispatch-repartition",
    "application_number": null
  },
  {
    "id": "doc:hc.cotellic",
    "type": "Document",
    "subtype": "Regulatory approval",
    "name": "Cotellic ",
    "aliases": [],
    "citation": "",
    "company": "",
    "drug_name_brand": "",
    "drug_name_generic": "",
    "first_published": "",
    "access_date": "",
    "organization_id": "hc",
    "publication_date": "",
    "url": "",
    "url_drug": "",
    "application_number": null
  }
]
